Welcome!

News Feed Item

Specialty Enzymes Market by Source (Microorganism, Plant, Animal), Type (Carbohydrases, Protease, Lipase, Polymerases & Nucleases), Application (Pharmaceutical, Research & biotechnology, Diagnostic, Bio-Catalyst) & Geography - Global Trends & Forecasts to

NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Specialty Enzymes Market by Source (Microorganism, Plant, Animal), Type (Carbohydrases, Protease, Lipase, Polymerases & Nucleases), Application (Pharmaceutical, Research & biotechnology, Diagnostic, Bio-Catalyst) & Geography - Global Trends & Forecasts to

http://www.reportlinker.com/p02116957/Specialty-Enzymes-Market-by-Source-Microorganism-Plant-Animal-Type-Carbohydrases-Protease-Lipase-Polymerases--Nucleases-Application-Pharmaceutical-Research--biotechnology-Diagnostic-Bio-Catalyst--Geography---Global-Trends--Forecasts-to.html

Specialty enzymes are natural proteins produced from micro organisms, plants and animals. An enzyme serves as catalysts for the chemical process that include the production of pharmaceuticals, diagnostics, research & biotechnology, and biocatalytic solutions. Enzymes increase reaction rates by decreasing the amount of energy required to form a complex of reactants that is competent to produce reaction products. Specialty enzymes according to their type are classified as carbohydrases, proteases, polymerases and nucleases, lipases, and others.

Specialty enzymes report covers analysis of the market structure by identifying various sub-segments of the global specialty enzymes market, Revenue forecasts of the global specialty enzymes markets and its various sub-markets/micro-markets with respect to four main regions- North America, Europe, Asia-Pacific, and Rest of the World (RoW). Major trends, drivers, and restraints of the global specialty enzymes market are identified and explained in detail.

The specialty enzyme markets include pharmaceutical, research and biotechnology, diagnostics and biocatalysts. Pharmaceutical manufacturers are witnessing increased awareness in incorporating biocatalysis into manufacturing processes. Enzymes are particularly useful to generate isomerically pure pharmaceuticals and fine chemicals In spite of numerous advantages of biocatalysis, manufacturers have been slow to adopt industrial-scale enzymatic approaches.

Specialty enzyme usage in the pharmaceutical industry is mainly for drug manufacture, disease diagnostics, or as therapy. Increasing implication of enzymes in therapies for diseases such as cancer, cardiovascular diseases, lysosomal storage disorders, pain and inflammation management, among others, is a tidal force that fuels market demand. Enzyme demand in the research and biotechnology end-market would benefit from the fall in DNA sequencing costs and the increase of new sequencing techniques. The vast majority of enzymes used in research and biotechnology, which spans over 80%of the demand, are devoted to DNA amplification and sequencing. This segment is led by DNA polymerases, which has experienced strong growth as new DNA sequencing techniques have been developed in recent years and the cost of DNA sequencing has dropped dramatically. The number of investigations is expected to increase, creating a strong business case for specialty enzymes

The North America is the largest market for specialty enzymes followed by Europe and Asia-Pacific respectively. Pharmaceuticals and diagnostics enzymes are expected to contribute more market share by 2018. Europe was the second largest market for the production and consumption of specialty enzymes.

The rising middle class population, increase in per capita income, rising healthcare expenditure, increasing prevalence of diseases, increasing affordability on the part of consumers, and rapid growth technologies find growing opportunities in Asia-Pacific and ROW. Countries such as China, India, South Africa, and Brazil have tremendous scope for the specialty enzyme market. The development of novel and superior performing products and rapid growing technology would enable specialty enzyme manufacturers to explore vast untapped potential of the emerging markets in Asia-Pacific and Latin American regions.

1 INTRODUCTION 14

1.1 KEY TAKE-AWAYS 14
1.2 REPORT DESCRIPTION 15
1.3 STAKEHOLDERS 16
1.4 RESEARCH METHDOLOGY 16
1.4.1 MARKETS COVERED 17
1.4.2 MARKETS SIZE 18
1.4.3 ASSUMPTIONS MADE FOR THE REPORT 18
1.4.4 KEY DATA POINTS VALIDATED FROM PRIMARY & SECONDARY SOURCES 19
1.4.5 KEY QUESTIONS ANSWERED 19

2 EXECUTIVE SUMMARY 20

3 PREMIUM INSIGHTS 22

3.1 NORTH AMERICA: THE PRODIGIOUS MARKET 22
3.2 THE NEXT FRONTIERS: BRAZIL, INDIA,& CHINA 23
3.3 PHARMACEUTICALS & DIAGNOSTICS-THE BIGGEST MARKET DRIVERS 24
3.4 MICRO-ORGANISMS- DOMINATING SOURCE OF ENZYMES 25

4 MARKET OVERVIEW 26

4.1 INTRODUCTION 27
4.2 DRIVERS 29
4.2.1 THE AGING APPLICATION FUELS THE PHARMACEUTICAL DIGNOSTIC ENZYMES DEMAND 30
4.2.2 ROBUST INVESTMENTS IN THE BIOTECH SECTOR PULLS THE DEMAND FOR ENZYMES 31
4.2.3 RAPID GROWTH IN THE PHARMACEUTICAL INDUSTRY 32
4.2.4 ADVANCEMENT IN ENZYME ENGINEERING & GREEN CHEMISTRY 33
4.3 OPPORTUNITIES 34
4.3.1 EMERGING REGIONAL MARKET 34
4.3.2 THE RISING CLINICAL IN VITRO DIAGNOSTICS INDUSTRY 34
4.3.3 RESTRAINS 35
4.3.4 RESTRICTED TEMPERATURE & THE PH OPERATIONAL RANGE OF ENZYMES 35
4.3.4.1 Legal & Ethical Issues 36
4.4 WINNING IMPERATIVE-GLOBAL PHARMACEUTICAL INDUSTRY OUTLOOK 37
4.5 PORTER'S FIVE FORCES ANALYSIS 39
4.5.1 DEGREE OF COMPETITION 40
4.5.2 BARGAINING POWER OF SUPPLIERS 40
4.5.3 BARGAINING POWER OF BUYERS 40
4.5.4 THREAT OF SUBSTITUTES 41
4.5.5 THREAT OF NEW ENTRANTS 41
4.6 MARKET SHARE ANALYSIS 42

5 GLOBAL SPECIALTY ENZYMES MARKET, BY SOURCE 44

5.1 INTRODUCTION 45
5.2 MICRO-ORGANISMS 47
5.3 PLANTS 49
5.4 ANIMALS 51

6 SPECIALTY ENZYME MARKET, BY TYPE 53

6.1 INTRODUCTION 54
6.2 CARBOHYDRASES 56
6.2.1 AMYLASES 57
6.2.2 CELLULASES 57
6.2.3 OTHER CARBOHYDRASES 58
6.3 PROTEASES 58
6.4 POLYMERASES &NUCLEASES 61
6.5 LIPASES 62
6.6 OTHERS 62
6.7 SPECIALTY ENZYMES USED IN PHARMACEUTICALS 64
6.8 SPECIALTY ENZYMES USED IN DIAGNOSTICS 65
6.9 SPECIALTY ENZYMES USED FOR RESEARCH & BIOTECHNOLOGY 66

7 SPECIALTY ENZYME MARKET, BY APPLICATION 67

7.1 INTRODUCTION 68
7.2 PHARMACEUTICALS 71
7.2.1 ENZYME REPLACEMENT THERAPY 73
7.2.2 THROMBOLYTIC ENZYMES 73
7.2.3 DIGESTIVE ENZYMES 73
7.3 RESEARCH & BIOTECHNOLOGY 74
7.4 DIAGNOSTIC 76
7.5 BIO-CATALYST 78

8 SPECIALTY ENZYMES MARKET, BY GEOGRAPHY 80

8.1 INTRODUCTION 81
8.2 NORTH AMERICA: SPECIALTY ENZYMES MARKET 82
8.2.1 U.S.: SPECIALTY ENZYME MARKET 85
8.2.2 CANADA: SPECIALTY ENZYME MARKET 87
8.2.3 MEXICO: SPECIALTYENZYMES MARKET 89
8.3 EUROPE: SPECIALTY ENZYME MARKET 91
8.3.1 GERMANY: SPECIALTY ENZYMES MARKET 94
8.3.2 U.K.: SPECIALTY ENZYMES MARKET 96
8.3.3 FRANCE: SPECIALTY ENZYMES MARKET 98
8.4 ASIA PACIFIC: SPECIALTY ENZYMES MARKET 101
8.4.1 CHINA:SPECIALTY ENZYME MARKET 104
8.4.2 INDIA:SPECIALTY ENZYME MARKET 106
8.4.3 JAPAN:SPECIALTY ENZYME MARKET 108
8.5 ROW : SPECIALTY ENZYMES MARKET 110
8.5.1 SOUTH AFRICA: SPECIALTY ENZYMES MARKET 113

9 COMPETITIVE LANDSCAPE 118

9.1 INTRODUCTION 119
9.2 AGREEMENTS, COLLABORATIONS, & PARTNERSHIPS: MOST PREFERRED STRATEGIC APPROACH 119
9.2.1 MAXIMUM DEVELOPMENTS IN 2012 121
9.2.2 SANOFI & LIFE TECHNOLOGIES -THE MOST ACTIVE PLAYERS 122
9.3 ACQUISTIONS 123
9.4 NEW PRODUCTS LAUNCH & PRODUCT DEVELOPMENTS 126
9.5 AGREEMENTS, PARTNERSHIPS, & COLLABORATIONS 127
9.6 EXPANSIONS & OTHER DEVELOPMENTS 131

10 COMPANY PROFILES 134 (Overview, Financials, Products & Services, Strategy, and Developments)*

10.1 BASF 134
10.2 AMANO ENZYME INC. 139
10.3 CODEXIS INC. 142
10.4 SANOFI S.A. 145
10.5 ROCHE HOLDING AG. 151
10.6 ADVANCED ENZYME TECHNOLOGY LTD. 155
10.7 LIFE TECHNOLOGIES 158
10.8 NAGASE & CO. LTD. 163
10.9 BBI ENZYMES LTD. 167
10.10 AFFYMETRIX INC. 169
*Details on overview, financials, product & services, strategy, and developments might not be captured in case of unlisted companies.

LIST OF TABLES

TABLE 1 GLOBAL POPULATION AGED 60 OR OVER, 2012-2050 30
TABLE 2 GROWTH IN ESTABLISHED BIOTECHNOLOGY CENTRES,
2011-2012 ($BILLION) 31
TABLE 3 OUTLOOK OF THE GLOBAL USE OF MEDICINES, BY GEOGRAPHY,
2007-2016($ BILLION) 32
TABLE 4 BIO-CATALYST ALIGNMENT WITH GREEN CHEMISTRY 33
TABLE 5 GLOBAL PHARMACEUTICAL DEMAND, BY THERAPEUTIC SEGMENT, 2000-2020 ($BILLION) 38
TABLE 6 GLOBAL SPECIALTY ENZYMES MARKET REVENUE, BY SOURCE,
2011-2018 ($MILLION) 46
TABLE 7 MICRO-ORGANISM-BASED SPECIALTY ENZYMES & THEIR APPLICATIONS 47
TABLE 8 MICRO-ORGANISM-BASED SPECIALTY ENZYMES MARKET,
BY GEOGRAPHY, 2011-2018 ($MILLION) 48

TABLE 9 PLANT-BASED SPECIALTY ENZYMES MARKET, BY GEOGRAPHY,
2011-2018 ($MILLION) 50
TABLE 10 ANIMAL BASED SPECIALTY ENZYMES MARKET, BY GEOGRAPHY,
2011-2018 ($ MILLION) 52
TABLE 11 GLOBAL SPECIALTY ENZYMES MARKET VALUE, BY TYPE,
2011–2018 ($MILLION) 55
TABLE 12 CARBOHYDRASES ENZYMES MARKET VALUE, BY GEOGRAPHY,
2011–2018($MILLION) 56
TABLE 13 TYPE OF PROTEASE &THEIR SPECIFICITY 59
TABLE 14 PROTEASES ENZYMES MARKET VALUE,BY GEOGRAPHY,
2011–2018($MILLION) 60
TABLE 15 POLYMERASES & NUCLEASES ENZYMES MARKET VALUE,
BY GEOGRAPHY,2011–2018($MILLION) 61
TABLE 16 OTHERS ENZYMES MARKET VALUE,BY GEOGRAPHY,
2011–2018($MILLION) 63
TABLE 17 GLOBAL PHARMACEUTICAL SPECIALTY ENZYMES MARKET VALUE,
BY TYPE,2011–2018($MILLION) 64
TABLE 18 GLOBAL DIAGNOSTIC SPECIALTY ENZYMES MARKET VALUE,BY TYPE, 2011–2018 ($MILLION) 65
TABLE 19 GLOBAL RESEARCH & BIOTECHNOLOGY SPECIALTY ENZYMES MARKET VALUE, BY TYPE, 2011–2018 ($MILLION) 66

TABLE 20 SPECIALTY ENZYMES MARKET, BY APPLICATION,
2011-2018 ($MILLION) 69
TABLE 21 PHARMACEUTICALS: SPECIALTY ENZYMES MARKET, BY GEOGRAPHY, 2011-2018 ($MILLION) 71
TABLE 22 PHARMACEUTICALS: GLOBAL SPECIALTY ENZYMES MARKET,
BY APPLICATION, 2011-2018 ($MILLION) 72
TABLE 23 RESEARCH & BIOTECHNOLOGY: SPECIALTY ENZYMES MARKET,
BY GEOGRAPHY, 2011-2018 ($MILLION) 75
TABLE 24 DIAGNOSTICS: SPECIALTY ENZYMES MARKET, BY GEOGRAPHY,
2011-2018 ($MILLION) 77
TABLE 25 BIO-CATALYSTS: SPECIALTY ENZYMES MARKET, BY GEOGRAPHY,
2011-2018 ($MILLION) 78
TABLE 26 NORTH AMERICA: SPECIALTY ENZYME MARKET, BY COUNTRY,
2011-2018 ($MILLION) 82
TABLE 27 NORTH AMERICA: SPECIALTY ENZYME MARKET, BY APPLICATION, 2011-2018 ($MILLION) 83
TABLE 28 NORTH AMERICA:SPECIALTY ENZYME MARKET, BY SOURCE,
2011-2018 ($MILLION) 84
TABLE 29 U.S.: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 85
TABLE 30 U.S.: SPECIALTY ENZYME MARKET, BY SOURCE, 2011-2018 ($MILLION) 86
TABLE 31 CANADA: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 87

TABLE 32 CANADA: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018 ($MILLION) 88
TABLE 33 MEXICO: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 89
TABLE 34 MEXICO: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018 ($MILLION) 90
TABLE 35 EUROPE: SPECIALTY ENZYMES MARKET, BY COUNTRY,
2011-2018 ($MILLION) 91
TABLE 36 EUROPE: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 92
TABLE 37 EUROPE:SPECIALTY ENZYME MARKET, BY SOURCE,
2011-2018 ($MILLION) 93
TABLE 38 GERMANY: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 94
TABLE 39 GERMANY: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018 ($MILLION) 95
TABLE 40 U.K.: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 96
TABLE 41 U.K.: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018 ($MILLION) 97

TABLE 42 FRANCE: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 98
TABLE 43 FRANCE: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018 ($MILLION) 99
TABLE 44 OTHERS EU: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018 ($MILLION) 100
TABLE 45 ASIA-PACIFIC: SPECIALTY ENZYMES MARKET, BY COUNTRY,
2011-2018 ($MILLION) 101
TABLE 46 ASIA-PACIFIC: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 102
TABLE 47 ASIA-PACIFIC: SPECIALTY ENZYME MARKET, BY SOURCE,
2011-2018 ($MILLION) 103
TABLE 48 CHINA: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 104
TABLE 49 CHINA: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018($MILLION) 105
TABLE 50 INDIA: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 106

TABLE 51 INDIA: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018 ($MILLION) 107
TABLE 52 JAPAN: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 108
TABLE 53 OTHERS APAC: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018 ($MILLION) 109
TABLE 54 ROW: SPECIALTY ENZYMES MARKET, BY COUNTRY,
2011-2018 ($MILLION) 110
TABLE 55 ROW: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 111
TABLE 56 ROW: SPECIALTY ENZYME MARKET, BY SOURCE,
2011-2018 ($MILLION) 112
TABLE 57 SOUTH AFRICA: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 113
TABLE 58 SOUTH AFRICA: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018 ($MILLION) 114
TABLE 59 BRAZIL: SPECIALTY ENZYME MARKET, BY APPLICATION,
2011-2018 ($MILLION) 115
TABLE 60 BRAZIL: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018 ($MILLION) 116
TABLE 61 OTHERS ROW: SPECIALTY ENZYMES MARKET, BY SOURCE,
2011-2018 ($MILLION) 117

TABLE 62 MERGERS & ACQUISITIONS, 2009–2013 123
TABLE 63 NEW PRODUCTS LAUNCH & PRODUCT DEVELOPMENTS, 2009–2013 126
TABLE 64 AGREEMENTS, PARTNERSHIPS, & COLLABORATIONS, 2009–2013 127
TABLE 65 EXPANSIONS & OTHER DEVELOPMENTS, 2009–2013 131
TABLE 66 BASF: PRODUCTS & THEIR DESCRIPTION 135
TABLE 67 AMANO ENZYME: PRODUCTS & THEIR APPLICATIONS 140
TABLE 68 SOUFFLET GROUP: PRODUCTS & THEIR DESCRIPTION 143
TABLE 69 SANOFI: PRODUCTS & THEIR DESCRIPTION 146
TABLE 70 ROCHE: PRODUCTS & THEIR DESCRIPTION 152
TABLE 71 ADVANCED ENZYMES TECHNOLOGY LTD.: PRODUCTS & THEIR DESCRIPTION 156
TABLE 72 LIFE TECHNOLOGIES LTD.: PRODUCTS & THEIR DESCRIPTION 159
TABLE 73 NAGASE & CO. LTD.: PRODUCTS & THEIR DESCRIPTION 164
TABLE 74 BBI ENZYMES LTD.: PRODUCTS & THEIR DESCRIPTION 168
TABLE 75 AFFYMETRIX: PRODUCTS & THEIR DESCRIPTION 170

LIST OF FIGURES

FIGURE 1 GLOBAL SPECIALTY ENZYMES MARKET,BY GEOGRAPHY, 2012 20
FIGURE 2 GLOBAL SPECIALTY ENZYME MARKET VALUE, BY GEOGRAPHY,
2012-2018 ($MILLION) 22
FIGURE 3 SPECIALTY ENZYME MARKET VALUE, BY COUNTRY,
2012 VS 2018($MILLION) 23
FIGURE 4 SPECIALTY ENZYME MARKET, BY APPLICATION, 2012-2018 ($MILLION) 24
FIGURE 5 SPECIALTY ENZYME MARKET VALUE, BY TYPE, 2012-2018 ($MILLION) 25
FIGURE 6 SPECIALTY ENZYME MARKET SEGMENTATION 28
FIGURE 7 DRIVERS & RESTRAINTS FOR SPECIALTY ENZYMES 29
FIGURE 8 EFFECT OF TEMPERATURE ON THE RATE OF AN ENZYME-CATALYZED REACTION 35
FIGURE 9 EFFECT OF PH ON THE RATE OF AN ENZYME-CATALYZED REACTION 36
FIGURE 10 PORTER'S FIVE FORCES ANALYSIS 39
FIGURE 11 SPECIALTY ENZYMES: GLOBAL MARKET SHARE ANALYSIS,
BY COMPANY, 2012 42
FIGURE 12 SPECIALTY ENZYMES, BY APPLICATION 68
FIGURE 13 SPECIALTY ENZYMES MARKET SHARE, BY APPLICATION, 2012 70
FIGURE 14 SPECIALITY ENZYMES MARKET SHARE, BY GROWTH STRATEGY,
2010–2013 120
FIGURE 15 SPECIALITY ENZYMES MARKET DEVELOPMENTS, 2009–2013 121
FIGURE 16 SPECIALITY ENZYMES DEVELOPMENT SHARE, BY COMPANY, 2009-2013 122
FIGURE 17 BASF: SWOT ANALYSIS 138
FIGURE 18 SANOFI: SWOT ANALYSIS 150
FIGURE 19 ROCHE: SWOT ANALYSIS 154
FIGURE 20 LIFE TECHNOLOGIES: SWOT ANALYSIS 162
FIGURE 21 NAGASE: SWOT ANALYSIS 166

To order this report: Specialty Enzymes Market by Source (Microorganism, Plant, Animal), Type (Carbohydrases, Protease, Lipase, Polymerases & Nucleases), Application (Pharmaceutical, Research & biotechnology, Diagnostic, Bio-Catalyst) & Geography - Global Trends & Forecasts to
http://www.reportlinker.com/p02116957/Specialty-Enzymes-Market-by-Source-Microorganism-Plant-Animal-Type-Carbohydrases-Protease-Lipase-Polymerases--Nucleases-Application-Pharmaceutical-Research--biotechnology-Diagnostic-Bio-Catalyst--Geography---Global-Trends--Forecasts-to.html

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
One of the biggest challenges with adopting a DevOps mentality is: new applications are easily adapted to cloud-native, microservice-based, or containerized architectures - they can be built for them - but old applications need complex refactoring. On the other hand, these new technologies can require relearning or adapting new, oftentimes more complex, methodologies and tools to be ready for production. In his general session at @DevOpsSummit at 20th Cloud Expo, Chris Brown, Solutions Marketi...
At the keynote this morning we spoke about the value proposition of Nutanix, of having a DevOps culture and a mindset, and the business outcomes of achieving agility and scale, which everybody here is trying to accomplish," noted Mark Lavi, DevOps Solution Architect at Nutanix, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
HyperConvergence came to market with the objective of being simple, flexible and to help drive down operating expenses. It reduced the footprint by bundling the compute/storage/network into one box. This brought a new set of challenges as the HyperConverged vendors are very focused on their own proprietary building blocks. If you want to scale in a certain way, let's say you identified a need for more storage and want to add a device that is not sold by the HyperConverged vendor, forget about it...
Enterprises are moving to the cloud faster than most of us in security expected. CIOs are going from 0 to 100 in cloud adoption and leaving security teams in the dust. Once cloud is part of an enterprise stack, it’s unclear who has responsibility for the protection of applications, services, and data. When cloud breaches occur, whether active compromise or a publicly accessible database, the blame must fall on both service providers and users. In his session at 21st Cloud Expo, Ben Johnson, C...
It is of utmost importance for the future success of WebRTC to ensure that interoperability is operational between web browsers and any WebRTC-compliant client. To be guaranteed as operational and effective, interoperability must be tested extensively by establishing WebRTC data and media connections between different web browsers running on different devices and operating systems. In his session at WebRTC Summit at @ThingsExpo, Dr. Alex Gouaillard, CEO and Founder of CoSMo Software, presented ...
In this presentation, you will learn first hand what works and what doesn't while architecting and deploying OpenStack. Some of the topics will include:- best practices for creating repeatable deployments of OpenStack- multi-site considerations- how to customize OpenStack to integrate with your existing systems and security best practices.
As you move to the cloud, your network should be efficient, secure, and easy to manage. An enterprise adopting a hybrid or public cloud needs systems and tools that provide: Agility: ability to deliver applications and services faster, even in complex hybrid environments Easier manageability: enable reliable connectivity with complete oversight as the data center network evolves Greater efficiency: eliminate wasted effort while reducing errors and optimize asset utilization Security: implemen...
Your homes and cars can be automated and self-serviced. Why can't your storage? From simply asking questions to analyze and troubleshoot your infrastructure, to provisioning storage with snapshots, recovery and replication, your wildest sci-fi dream has come true. In his session at @DevOpsSummit at 20th Cloud Expo, Dan Florea, Director of Product Management at Tintri, provided a ChatOps demo where you can talk to your storage and manage it from anywhere, through Slack and similar services with...
Most people haven’t heard the word, “gamification,” even though they probably, and perhaps unwittingly, participate in it every day. Gamification is “the process of adding games or game-like elements to something (as a task) so as to encourage participation.” Further, gamification is about bringing game mechanics – rules, constructs, processes, and methods – into the real world in an effort to engage people. In his session at @ThingsExpo, Robert Endo, owner and engagement manager of Intrepid D...
Recently, WebRTC has a lot of eyes from market. The use cases of WebRTC are expanding - video chat, online education, online health care etc. Not only for human-to-human communication, but also IoT use cases such as machine to human use cases can be seen recently. One of the typical use-case is remote camera monitoring. With WebRTC, people can have interoperability and flexibility for deploying monitoring service. However, the benefit of WebRTC for IoT is not only its convenience and interopera...
Evan Kirstel is an internationally recognized thought leader and social media influencer in IoT (#1 in 2017), Cloud, Data Security (2016), Health Tech (#9 in 2017), Digital Health (#6 in 2016), B2B Marketing (#5 in 2015), AI, Smart Home, Digital (2017), IIoT (#1 in 2017) and Telecom/Wireless/5G. His connections are a "Who's Who" in these technologies, He is in the top 10 most mentioned/re-tweeted by CMOs and CIOs (2016) and have been recently named 5th most influential B2B marketeer in the US. H...
Michael Maximilien, better known as max or Dr. Max, is a computer scientist with IBM. At IBM Research Triangle Park, he was a principal engineer for the worldwide industry point-of-sale standard: JavaPOS. At IBM Research, some highlights include pioneering research on semantic Web services, mashups, and cloud computing, and platform-as-a-service. He joined the IBM Cloud Labs in 2014 and works closely with Pivotal Inc., to help make the Cloud Found the best PaaS.
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
"With Digital Experience Monitoring what used to be a simple visit to a web page has exploded into app on phones, data from social media feeds, competitive benchmarking - these are all components that are only available because of some type of digital asset," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Everything run by electricity will eventually be connected to the Internet. Get ahead of the Internet of Things revolution. In his session at @ThingsExpo, Akvelon expert and IoT industry leader Sergey Grebnov provided an educational dive into the world of managing your home, workplace and all the devices they contain with the power of machine-based AI and intelligent Bot services for a completely streamlined experience.